The Real Gap Isn't Evidence. It's Framework Fit.

Three frameworks, one moving target

FDA has cleared roughly 1,500 AI-enabled medical devices, and a recent review notes that post-market evidence for most of them is still catching up to the claims made at clearance Clinical Trial Vanguard. That gap is real, but treating it as the headline risks missing the larger problem underneath it. FDA has also opened a public inquiry into whether generative AI tools used clinically should be regulated as devices at all, explicitly stating the document is neither draft nor final guidance, just a set of questions to physicians, manufacturers, and researchers Radiology Business. Separate reporting frames the same inquiry as the agency weighing rules for a category of software that has largely sat outside traditional SaMD review BankInfoSecurity. Three different regulatory postures, applied to overlapping technology, in the same agency, at the same time.

The rigor-agility tension is not FDA-specific

Look past the U.S. and the pattern repeats with more friction, not less. Industry analysis of the medtech landscape describes a persistent paradox between regulatory rigor and the pace of development that AI-enabled tools demand MDDI Online. Under the EU’s Medical Device Regulation, that rigor is not abstract. One manufacturer described needing roughly 2,000 pages of documentation to bring a simple cannula to market, a burden predating any AI component heise online. Regulators are responding with purpose-built tracks. New guidance is emerging specifically around AI-specific authorisation routes, an acknowledgment that the existing device pathway was not built for adaptive software Medical Buyer. None of these efforts are converging on a shared standard. Developers building for multiple markets are being told to plan for divergence, not harmonization BioSpace.

Hospitals are not waiting for the frameworks to catch up

While regulators debate classification, deployment is already happening. Sheba Medical Center became OpenAI’s first international hospital partner, putting generative AI into clinical workflows well ahead of any settled device status for that category of tool Drug Discovery Trends. That is not a criticism of Sheba. It is the honest state of the field. Clinical deployment is moving on its own timeline, and the compliance function inherits the gap regulators haven’t closed yet.

What this means for the deployment decision

A cleared device with a Predetermined Change Control Plan still needs independent monitoring against your own patient population, because PCCP governs sanctioned drift, not real-world performance Clinical Trial Vanguard. A generative AI tool with no device status yet needs the same rigor, built voluntarily, because no jurisdiction has finished deciding whose job that is. The frameworks will eventually catch up to each other. The evidence discipline in your own health system cannot wait for that to happen.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The argument is coherent and logically structured—framework fragmentation is established through concrete examples, the rigor-agility tension is shown to be systemic rather than FDA-specific, and the
Source & Claim Verification	Qwen · local	cleared. All factual claims are supported by citations, but some sources are redundant and could be streamlined for clarity.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the current regulatory fragmentation but does not explicitly map its observations to ISO 42001, EU AI Act, or MDR/IVDR requirements.
Technical Accuracy	Llama	cleared. The article accurately reflects current challenges in regulating AI-enabled medical devices and generative AI tools, citing relevant sources and industry concerns.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and counters potential vendor hype by focusing on the practical challenges and regulatory gaps rather than uncritically accepting technological advancements.
Novelty & Non-Duplication	Grok	held. Competent wire synthesis of already-circulating FDA/EU AI-device lag and hospital-deployment-ahead-of-rules stories; the ‘framework fit’ reframe is incremental, not a distinctive non-duplicative angle
Validation	DeepSeek	cleared. The central claim that regulatory frameworks are fragmented and lagging behind deployment is strongly supported by multiple, credible reports of divergent regulatory postures and real-world hospital a

Sources cited: 14. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.